Patents by Inventor Steven K. White
Steven K. White has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20130338125Abstract: The invention provides and describes solid state 17?-ethynyl-5?-androstane-3?,17?-diol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17?-ethynyl-5?-androstane-3?,17?-diol include Form III anhydrate and Form I solvate. The invention further relates to solid and suspension formulations containing 17?-ethynyl-5?-androstane-3?,17?-diol in a described solid state form and use of the formulations to treat cancers or precancers such as prostate cancer or breast cancer in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17?-ethynyl-5?-androstane-3?,17?-diol and uses of such formulations in treating the described conditions.Type: ApplicationFiled: June 17, 2013Publication date: December 19, 2013Inventors: Steven K. White, Dwight Stickney
-
Publication number: 20130066087Abstract: The invention relates to processes for preparing 17-alkynyl-7-hydroxy-steroids, such as 17-Ethynyl-10R,13S-dimethyl 2,3,4,7,8R,9S,10,11,12,13,14S,15,16,17-hexadecahydro-1H-cyclopenta[a]phenanthrene-3R,7R,17S-triol (also referred to as 17?-ethynyl-androst-5-ene-3?,7?,17?-triol), that are essentially free of process impurities having binding activity at nuclear estrogen receptors.Type: ApplicationFiled: October 30, 2012Publication date: March 14, 2013Applicant: Harbor Therapeutics, Inc.Inventors: Steven K. White, Yu Ge, Yujin Huang
-
Publication number: 20120302537Abstract: The invention provides and describes solid state 17?-ethynyl-androst-5-ene-3?,7?,17?-triol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17?-ethynyl-androst-5-ene-3?,7?,17?-triol include Form I anhydrate and Form IV and Form V solvates. The invention further relates to solid and suspension formulations containing 17?-ethynyl-androst-5-ene-3?,7?,17?-triol in a described solid state form and use of the formulations to treat hyperglycemic conditions, such as type 2 diabetes and metabolic syndrome, and autoimmune conditions, such as rheumatoid arthritis, ulcerative colitis and type 1 diabetes, among other inflammation related conditions in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17?-ethynyl-androst-5-ene-3?,7?,17?-triol and uses of such formulations in treating the described conditions.Type: ApplicationFiled: August 1, 2012Publication date: November 29, 2012Applicant: Harbor Therapeutics, Inc.Inventors: Steven K. White, Igor Ivanisevic, Kyle Stephens, Mark Andres, Brenton Skylar Wolfe
-
Publication number: 20120296105Abstract: The invention provides and describes solid state 17?-ethynyl-androst-5-ene-3?,7?,17?-triol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17?-ethynyl-androst-5-ene-3?,7?,17?-triol include Form I anhydrate and Form IV and Form V solvates. The invention further relates to solid and suspension formulations containing 17?-ethynyl-androst-5-ene-3?,7?,17?-triol in a described solid state form and use of the formulations to treat hyperglycemic conditions, such as type 2 diabetes and metabolic syndrome, and autoimmune conditions, such as rheumatoid arthritis, ulcerative colitis and type 1 diabetes, among other inflammation related conditions in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17?-ethynyl-androst-5-ene-3?,7?,17?-triol and uses of such formulations in treating the described conditions.Type: ApplicationFiled: August 1, 2012Publication date: November 22, 2012Applicant: Harbor Therapeutics, Inc.Inventors: Steven K. White, Igor Ivanisevic, Kyle Stephens, Mark Andres, Brenton Skylar Wolfe
-
Patent number: 8309746Abstract: The invention relates to processes for preparing 17-alkynyl-7-hydroxy-steroids, such as 17-Ethynyl-10R,13S-dimethyl 2,3,4,7,8R,9S, 10,11,12,13,14S,15,16,17-hexadecahydro-1H-cyclopenta[a]phenanthrene-3R, 7R,17S-triol (also referred to as 17?-ethynyl-androst-5-ene-3?,7?,17?-triol), that are essentially free of process impurities having binding activity at nuclear estrogen receptors.Type: GrantFiled: June 5, 2009Date of Patent: November 13, 2012Assignee: Harbor Therapeutics, IncInventors: Steven K. White, Yu Ge, Yujin Huang
-
Publication number: 20120252774Abstract: The invention relates to solid state forms of androst-5-ene-3?,7?,16?,17?-tetrol, formulations containing or prepared from such solid state forms and use of these materials for modulating unwanted inflammation including acute and chronic non-productive inflammation. The formulations can be used to prevent, treat or slow the progression of conditions related to autoimmunity and metabolic disorders such as arthritis, multiple sclerosis, ulcerative colitis, Type 1 diabetes and Type 2 diabetes.Type: ApplicationFiled: December 16, 2011Publication date: October 4, 2012Inventors: Steven K. White, Erin E. Jansen
-
Publication number: 20120220560Abstract: The invention relates to solid state forms of androst-5-ene-3?,7?,16?,17?-tetrol, formulations containing or prepared from such solid state forms and use of these materials for modulating unwanted inflammation including acute and chronic non-productive inflammation. The formulations can be used to prevent, treat or slow the progression of conditions related to autoimmunity and metabolic disorders such as arthritis, multiple sclerosis, ulcerative colitis, Type 1 diabetes and Type 2 diabetes.Type: ApplicationFiled: December 16, 2011Publication date: August 30, 2012Inventors: Steven K. White, Erin E. Jansen
-
Patent number: 8252947Abstract: The invention provides and describes solid state 17?-ethynyl-androst-5-ene-3?, 7?,17?-triol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17?-ethynyl-androst-5-ene-3?, ?,17?-triol include Form I anhydrate and Form IV and Form V solvates. The invention further relates to solid and suspension formulations containing 17?-ethynyl-androst-5-ene-3?,7?,17?-triol in a described solid state form and use of the formulations to treat hyperglycemic conditions, such as type 2 diabetes and metabolic syndrome, and autoimmune conditions, such as rheumatoid arthritis, ulcerative colitis and type 1 diabetes, among other inflammation related conditions in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17?-ethynyl-androst-5-ene-3?, 7?,17?-triol and uses of such formulations in treating the described conditions.Type: GrantFiled: April 3, 2009Date of Patent: August 28, 2012Assignee: Harbor Therapeutics, Inc.Inventors: Steven K. White, Igor Ivanisevic, Kyle Stephens, Mark Andres, Brenton Skylar Wolfe
-
Publication number: 20120214987Abstract: The invention relates to processes for preparing 3?-O-linked steroids including 3?-O-linked-androst-5-ene steroids and 3?-O-linked-5a-androstane steroids. In one process a 3?,4?-epoxy androst-5-en-17-one is predominately reduced at the epoxy moiety wherein reduction of the 3?,4? epoxy functional group occurs preferentially at position C4 with retention of configuration at position C3 to provide a 3?-O-linked-androst-5-ene steroid. In another process, conditions are provided for inversion of configuration of a 3?-hydroxy-androst-5-ene steroid by the Mitsunobu reaction to provide a 3?-O-linked-androst-5-ene steroid with reduced amounts of 3?,5?-cycloandrostane side-product impurities.Type: ApplicationFiled: December 15, 2011Publication date: August 23, 2012Inventors: Yu Ge, Steven K. White, Yujin Huang
-
Publication number: 20090326251Abstract: The invention relates to processes for preparing 17-alkynyl-7-hydroxy-steroids, such as 17-Ethynyl-10R,13S-dimethyl 2,3,4,7,8R,9S, 10,11,12,13,14S,15,16,17-hexadecahydro-1H-cyclopenta[a]phenanthrene-3R,7R,17S-triol (also referred to as 17?-ethynyl-androst-5-ene-3?,7?,17?-triol), that are essentially free of process impurities having binding activity at nuclear estrogen receptors.Type: ApplicationFiled: June 5, 2009Publication date: December 31, 2009Applicant: Hollis-Eden Pharmaceuticals, Inc.Inventors: Steven K. White, Yu Ge, Yujin Huang
-
Publication number: 20090291933Abstract: The invention provides and describes solid state 17?-ethynyl-androst-5-ene-3?,7?,17?-triol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17?-ethynyl-androst-5-ene-3?,7?,17?-triol include Form I anhydrate and Form IV and Form V solvates. The invention further relates to solid and suspension formulations containing 17?-ethynyl-androst-5-ene-3?,7?,17?-triol in a described solid state form and use of the formulations to treat hyperglycemic conditions, such as type 2 diabetes and metabolic syndrome, and autoimmune conditions, such as rheumatoid arthritis, ulcerative colitis and type 1 diabetes, among other inflammation related conditions in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17?-ethynyl-androst-5-ene-3?,7?,17?-triol and uses of such formulations in treating the described conditions.Type: ApplicationFiled: April 3, 2009Publication date: November 26, 2009Applicant: Hollis-Eden Pharmaceuticals, Inc.Inventors: Steven K. White, Igor Ivanisevic, Kyle Stephens, Mark Andres, Brenton Skylar Wolfe
-
Publication number: 20090291932Abstract: The invention provides and describes solid state 17?-ethynyl-5?-androstane-3?,17?-diol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17?-ethynyl-5?-androstane-3?,17?-diol include Form III anhydrate and Form I solvate. The invention further relates to solid and suspension formulations containing 17?-ethynyl-5?-androstane-3?,17?-diol in a described solid state form and use of the formulations to treat cancers or precancers such as prostate cancer or breast cancer in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17?-ethynyl-5?-androstane-3?,17?-diol and uses of such formulations in treating the described conditions.Type: ApplicationFiled: February 12, 2009Publication date: November 26, 2009Applicant: HollisEden Pharmaceuticals, INC.Inventors: Steven K. White, Dwight Stickney, Erin Olson, Keith Richard Lorimer, Brenton Skylar Wolfe
-
Publication number: 20090258850Abstract: The invention relates to pharmaceutically acceptable formulations comprising an active pharmaceutical ingredient such as androst-5-ene-3?,17?-diol, androst-5-ene-3?,7?,17?-triol or derivatives of either of these compounds and an air oxidizable excipient that have been stabilized with respect to efficacy. Use of the efficacy-stabilized formulations to treat a number of conditions or symptoms thereof, such as a symptom associated with exposure to radiation is described.Type: ApplicationFiled: August 21, 2008Publication date: October 15, 2009Inventors: James M. Frincke, Steven K. White, Yu Ge, Weicheng Liaw, Tao Hu
-
Patent number: 7547687Abstract: The invention relates to the use of compounds to ameliorate or treat a condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3?-hydroxy-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 1?,3?-dihydroxy-4?-fluoroandrost-5-ene-17-one, 1?,3?,17?-trihydroxy-4?-fluoroandrost-5-ene, 1?,3?-dihydroxy-6?-bromoandrost-5-ene, 1?-fluoro-3?,12?-dihydroxyandrost-5-ene-17-one, 1?-fluoro-3?,4?-dihydroxyandrost-5-ene and 4?-fluoro-3?,6?,17?-trihydroxyandrostane.Type: GrantFiled: February 12, 2007Date of Patent: June 16, 2009Assignee: Hollis-Eden Pharmaceuticals, Inc.Inventors: Christopher L. Reading, Clarence N. Ahlem, Dominick L. Auci, Charles Dowding, James M. Frincke, Mei Li, Theodore M. Page, Dwight R. Stickney, Richard J. Trauger, Steven K. White
-
Patent number: 7482334Abstract: The invention relates to the use of compounds to ameliorate or treat a condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3?-hydroxy-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 1?,3?-dihydroxy-4?-fluoroandrost-5-ene-17-one, 1?,3?,17?-trihydroxy-4?-fluoroandrost-5-ene, 1?,3?-dihydroxy-6?-bromoandrost-5-ene, 1?-fluoro-3?,12?-dihydroxyandrost-5-ene-17-one, 1?-fluoro-3?,4?-dihydroxyandrost-5-ene and 4?-fluoro-3?,6?,17?-trihydroxyandrostane.Type: GrantFiled: February 12, 2007Date of Patent: January 27, 2009Assignee: Hollis-Eden Pharmaceuticals, Inc.Inventors: James M. Frincke, Steven K. White
-
Publication number: 20080090791Abstract: The invention relates to the use of compounds to ameliorate or treat an condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3?-hydroxy-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 1?,3?-dihydroxy-4?-fluoroandrost-5-ene-17-one, 1?,3?,17?-trihydroxy-4?-fluoroandrost-5-ene, 1?,3?-dihydroxy-6?-bromoandrost-5-ene, 1?-fluoro-3?,12?-dihydroxyandrost-5-ene-17-one, 1?-fluoro-3?,4?-dihydroxyandrost-5-ene and 4?-fluoro-3?,6?,17?-trihydroxyandrostane.Type: ApplicationFiled: October 13, 2006Publication date: April 17, 2008Applicant: Hollis-Eden Pharmaceuticals, Inc.Inventors: Christopher L. Reading, Clarence N. Ahlem, Dominick L. Auci, Charles Dowding, James M. Frincke, Mei Li, Theodore Page, Dwight R. Stickney, Richard J. Trauger, Steven K. White
-
Publication number: 20080085873Abstract: The invention relates to the use of compounds to ameliorate or treat a condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3?-hydroxy-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 1?,3?-dihydroxy-4?-fluoroandrost-5-ene-17-one, 1?,3?,17?-trihydroxy-4?-fluoroandrost-5-ene, 1?,3?-dihydroxy-6?-bromoandrost-5-ene, 1?-fluoro-3?,12?-dihydroxyandrost-5-ene-17-one, 1?-fluoro-3?,4?-dihydroxyandrost-5-ene and 4?-fluoro-3?,6?, 17?-trihydroxyandrostane.Type: ApplicationFiled: October 13, 2006Publication date: April 10, 2008Applicant: Hollis-Eden Pharmaceuticals, Inc.Inventors: Christopher L. Reading, Clarence N. Ahlem, Dominick L. Auci, Charles Dowding, James M. Frincke, Mei Li, Theodore M. Page, Dwight R. Stickney, Richard J. Trauger, Steven K. White
-
Publication number: 20040138187Abstract: The invention relates to the use of compounds to ameliorate or treat an condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3&bgr;-hydroxy-17&bgr;-aminoandrost-5-ene, 3&bgr;-hydroxy-16&agr;-fluoro-17&bgr;-aminoandrost-5-ene, 3&agr;-hydroxy-16&agr;-fluoro-17&bgr;-aminoandrost-5-ene, 3&bgr;-hydroxy-16&bgr;-fluoro-17&bgr;-aminoandrost-5-ene, 1&agr;,3&bgr;-dihydroxy-4&agr;-fluoroandrost-5-ene-17-one, 1&agr;,3&bgr;,17&bgr;-trihydroxy-4&agr;-fluoroandrost-5-ene, 1&bgr;,3&bgr;-dihydroxy-6&agr;-bromoandrost-5-ene, 1&agr;-fluoro-3&bgr;,12&agr;-dihydroxyandrost-5-ene-17-one, 1&agr;-fluoro-3&bgr;,4&agr;-dihydroxyandrost-5-ene and 4&agr;-fluoro-3&bgr;,6&agr;,17&bgr;-trihydroxyandrostane.Type: ApplicationFiled: August 28, 2003Publication date: July 15, 2004Inventors: Christopher L. Reading, Clarence N. Ahlem, Dominick L. Auci, Charles Dowding, James M. Frincke, Mei Li, Theodore M. Page, Dwight R. Stickney, Richard J. Trauger, Steven K. White
-
Patent number: 5817845Abstract: Methods for stereospecific synthesis of 9-cis olefins and retinoids. In one particular aspect, a cis olefin is generated via a lactol ring opening with complete retention of double bond configuration.Type: GrantFiled: October 9, 1996Date of Patent: October 6, 1998Assignee: Ligand Pharmaceuticals, Inc.Inventors: Steven K. White, Chan Kou Hwang, David T. Winn
-
Patent number: 5770383Abstract: Tricyclic retinoids having activity for retinoic acid receptors and/or retinoid X receptors are provided. Also provided are pharmaceutical compositions incorporating such tricyclic retinoid compounds and methods for their therapeutic use.Type: GrantFiled: June 7, 1995Date of Patent: June 23, 1998Assignee: Ligand Pharmaceuticals, Inc.Inventors: Chan Kou Hwang, Steven K. White, Youssef L. Bennani, Stacie S. Canan Koch, Beth Ann Badea, Jonathan J. Hebert, Luc J. Farmer, Alex M. Nadzan